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Sorafenib, a multi-kinase inhibitor, is the only standard clinical drug for patients
with advanced hepatocellular carcinoma (HCC); however, development of sorafe-
nib resistance in HCC often prevents its long-term efﬁcacy. Therefore, novel tar-
gets and strategies are urgently needed to improve the antitumor effect of
sorafenib. In the present study, we examined the novel mechanisms of sorafenib
resistance of HCC cells by investigating the difference in sorafenib sensitivity
between two HCC cell lines. Sorafenib induced more apoptosis of HepG2 cells
compared to Hep3B cells. Sorafenib exposure to HepG2 cells but not Hep3B cells
increased the expression of proapoptotic factor PUMA, and activated PARP and
caspase-3. Notably, microRNA-181a (miR-181a) expression levels were lower in
HepG2 cells than in Hep3B cells. Exogenous miR-181a expression in HepG2 cells
reduced apoptosis, whereas inhibition of miR-181a in Hpe3B cells increased apop-
tosis. In addition, we demonstrated that miR-181a directly targets RASSF1, a
MAPK signaling factor, and knockdown of RASSF1 increased sorafenib resistance.
Taken together, these results suggest that miR-181a provokes sorafenib resis-
tance through suppression of RASSF1. Our data provide important insight into
the novel therapeutic strategy against sorafenib resistance of HCC cells by target-
ing of miR-181a pathway.
H epatocellular carcinoma (HCC) is the third most commoncause of cancer-related deaths worldwide.(1) Surgical
resection and liver transplantation are ﬁrst-line therapeutic
options for early stage HCC patients, and locoregional thera-
pies, including transarterial chemoembolization and radiofre-
quency ablation, are used to treat patients who are not suitable
for surgery.(2) Sorafenib is the ﬁrst systemic drug for patients
with advanced HCC.(3) Sorafenib inhibits the activity of multi-
kinases such as Raf kinase, vascular endothelial growth factor
receptor 2 (VEGFR2) and platelet-derived growth factor recep-
tor (PDGFR).(4) Although sorafenib could improve the overall
survival of HCC patients from 7.9 to 10.7 months, many
patients still do not beneﬁt from this therapy and acquired
resistance often develops within 6 months.(3,5) Therefore, iden-
tiﬁcation of signaling networks that are crucial for the antitu-
mor efﬁcacy of sorafenib will contribute to the rational design
of the novel therapeutic approach for HCC.
MicroRNA inhibit translation of target mRNA through
binding to their 30 untranslated regions (30UTR)(6) and
regulate critical cellular processes such as proliferation and
apoptosis in HCC cells.(7–11) Abnormal regulation of micro-
RNA may correlate with hepatocaricinogenesis and HCC
progression.(12) For example, microRNA-122 (miR-122)
expression is signiﬁcantly suppressed in HCC and this down-
regulation is associated with poor prognosis.(9–11) In addition,
several microRNA, such as miR-222, 1274a and 34a, affect
the drug sensitivity of HCC cells.(13–15) MiR-181a is highly
expressed in cancer stem cells of HCC(16) and induces
epithelial–mesenchymal transition in ovarian cancer.(17) It has
also been reported that miR-181a contributes to cancer pro-
gression and metastasis in a variety of cancers.(18,19) Nota-
bly, HCC cell line HepG2 cells express lower levels of
miR-181a(20) and are more sensitive to sorafenib compared
to Hep3B cells.(21) These reports suggest that miR-181a may
have a role in regulation of sorafenib resistance. In the pre-
sent study, we found that sorafenib induced more apoptosis
in HepG2 cells compared to Hep3B cells. Exogenous miR-
181a expression in HepG2 cells reduced apoptosis, whereas
inhibition of miR-181a in Hpe3B cells increased apoptosis.
We also showed that MAPK signaling factor RASSF1 is a
target of miR-181a and that knockdown of RASSF1 reduced
sorafenib sensitivity. These results suggest that miR-181a
plays a critical role in sorafenib resistance through suppres-
sion of RASSF1 in HCC cells.
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Materials and Methods
Cell culture. HepG2 and Hep3B cells were cultured in
DMEM (Nissui Pharmacetical, Tokyo, Japan) supplemented
with 10% FBS (MBL, Nagoya, Japan).
Cell viability assay. HepG2 and Hep3B cells were seeded
onto a 96-well plate at a density of 1 9 104 and 0.5 9 104
cells/well, respectively. After 72 h, viable cells were quantiﬁed
using the Cell Counting Kit-8 (Dojin Chemical, Kumamoto,
Japan) according to the manufacturer’s protocol. Absorbance
was measured at 450 nm with a reference wavelength of
600 nm using a microplate reader for 96-well plates (Tecan,
Zurich, Swizerland).
Transfection. HepG2 cells and Hep3B cells were transfected
with 100 nM pre-miR-181a or anti-miR-181a (Life Technolo-
gies, Carlsbad, CA, USA) using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s protocol. Cells
were transfected with 20 lM siRASSF1 and negative control
siRNA using Lipofectamine 2000.
Quantitative-RT PCR of miRNA. Total RNA was isolated from
the cells with TRIzol Reagent (Life Technologies). Expression
of miR-181a was detected using TaqMan MicroRNA Assays
(Applied Biosystems, Foster City, CA, USA), the MicroRNA
RT Kit (Applied Biosystems) and the Taqman Universal PCR
Master Mix II with UNG (Applied Biosystems) and the ABI
PRISM 7900HT Sequence Detection System (Applied Biosys-
tems) according to the manufacturer’s protocol. RNU6B was
used as an internal control.
Quantitative-RT PCR of mRNA. Total RNA was isolated from
the cells with TRIzol reagent. Expression of mRNA was
detected using SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) and FastStart SYBR Green
Master (Roche Diagnostics, Mannheim, Germany) by the
LightCycler 2.0 (Roche Diagnostics).
Heochst staining. Cells were treated with Hoechst 33342 for
30 min and photographed with a microscope (IX-71) (OLYM-
PUS, Tokyo, Japan) and analyzed using an image analysis sys-
tem (inForm 2.0) (PerkinElmer, Norwalk, CT, USA).
Caspase 3/7 activity analysis. Apoptosis was quantiﬁed using
the Caspase-Glo 3/7 Assay (Promega, Madison, WI, USA)
according to the manufacturer’s protocol.
Cell cycle analysis. 1 9 106 cells were ﬁxed with 70% EtOH
overnight at 4°C. Cells were treated with RNase for 30 min at
room temperature, stained with PI for 60 min and analyzed
using FACSAria (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA).
Western blot analysis. The primary antibodies used in this study
were polyclonal antibodies against human b-ACTIN, RASSF1
(Santa Cruz, CA, USA), ERK, phospho-ERK (Thr202/Tyr204),
caspase-3 and PARP (Cell Signaling Technology, Beverly, MA,
USA). HRP-labeled secondary antibodies were used for the detec-
tion of primary antibodies and the bands were detected by Image-
Quant LAS4000 (GE Healthcare UK, Little Chalfont, UK).
DNA constructs. For functional analysis of miR-181a, seg-
ments of the 30-UTR RASSF1 mRNA sequences were synthe-
sized. The products were then subcloned into the HindIII-XbaI
site of a pGL3-Promoter Vector (Promega).
Luciferase reporter assay. The cells were co-transfected with
ﬁreﬂy luciferase plasmid (Promega), renilla luciferase plasmid
and microRNA with Lipofectamine 2000, and luciferase assays
were performed with a dual-luciferase reporter assay system
(Promega) at 48 h after transfection, in accordance with the
Fig. 1. Sorafenib induced more apoptosis and
lower cell viability of HepG2 cells compared to
Hep3B cells. (a) HepG2 and Hep3B cells were
cultured with sorafenib (0–20 lM) for 72 h and cell
viability was analyzed by WST assay. (b, c) HepG2
and Hep3B cells were cultured with 0 or 5 lM of
soraﬁnib for 24 h (b) or 48 h (c) and the number of
apoptotic cells was quantiﬁed by Hoechst staining
and presented as a percentage of total cell
number. Seven ﬁelds were randomly chosen,
photographed from each group, and statistically
analyzed.*P < 0.05, compared between 0 and 5 lM
treatment of sorafenib. (d, e) Cell-cycle analysis was
performed by ﬂow cytometry using HepG2 cells (d)
or Hep3B cells (e) treated with 0 or 5 lM of
sorafenib for 48 h. *P < 0.05, compared between 0
and 5 lM treatment of sorafenib.
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manufacturer’s instructions. Luminescent signals were quanti-
ﬁed with a luminometer (MiniLumat LB9506; Berthold
GmbH&Co. KG, Wildbad, Germany), and each value for ﬁreﬂy
luciferase activity was normalized by renilla luciferase activity.
Statistical analysis. All the values were expressed as
mean  SD. The differences between the two groups were
analyzed using an unpaired two-tailed Student’s t-test. A
P-value <0.05 was considered to be signiﬁcant.
Results
Sorafenib induced more apoptosis and lower cell viability of
HepG2 cells compared to Hep3B cells. To examine the sorafenib
sensitivity of HepG2 cells and Hep3B cells, cell viability assay
was performed. HepG2 and Hep3B cells were cultured with
sorafenib (0–20 lM) for 72 h and assayed by Cell Counting
Kit-8. HepG2 cells showed higher sensitivity to sorafenib than
Hep3B cells, which is consistent with a previous report
(Fig. 1a).(21) Next, we investigated whether apoptosis is
induced by sorafenib treatment. Cells were stained with
Hoechst and apoptotic cells were analyzed. Sorafenib signiﬁ-
cantly increased the rate of apoptosis of HepG2 cells, but did
not increase the rate of apoptosis of Hep3B cells (Fig. 1b,c).
Consistently, cell cycle analysis by FACS revealed that sorafe-
nib-treated HepG2 cells clearly increased sub-G1 population,
while Hep3B cells did not. These results indicate that sorafenib
induced higher apoptotic rate and lower cell viability of
HepG2 cells compared to Hep3B cells (Fig. 1d,e).
Apoptosis related-molecules were increased/activated in sora-
fenib-treated HepG2 cells. Next, we examined expression levels
of apoptosis regulators with sorafenib treatment by western
blot analysis. Quantiﬁcation of western blot bands, which were
normalized by ACTIN, is shown in Figure 2a.Sorafenib inhi-
bits activity of RAF kinase, which reduces phosphorylation of
ERK (p-ERK). We conﬁrmed that p-ERK was reduced by
sorafenib treatment (Fig. 2a). Quantiﬁed data combined with
western blot clearly showed that sorafenib treatment
induced apoptosis markers, PUMA, cleaved-PARP and
Fig. 2. Apoptosis related-molecules were increased/
activated in sorafenib-treated HepG2 cells. (a)
Western blot analysis of phospho-ERK, ERK, PUMA,
PARP, caspase-3 and ACTIN using HepG2 or Hep3B
cells treated with 5 lM sorafenib for 0–24 h.
Quantiﬁcation of western blot bands using ImageJ
software (national institutes of health, Bethesda,
MD), which are normalized by ACTIN, were displayed
as bar graphs. (b) HepG2 and Hep3B cells were
treated with sorafenib (0 or 5 lM) for 48 h and
activities of caspase-3/7 were measured. *P < 0.05,
compared between 0 and 5 lM treatment of
sorafenib.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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cleaved-caspase-3 in HepG2 but not in Hep3B cells (Fig. 2a).
We also measured caspase-3/7 activity. Consistent with west-
ern blot analysis, caspase-3/7 activity was signiﬁcantly
increased in HepG2 cells but not in Hep3B cells with sorafenib
treatment (Fig. 2b,c). These results indicate that sorafenib
induced apoptosis of HepG2 cells through increase/activation
of proapoptotic factors.
miR-181a plays a critical role in sorafenib resistance. It has
been reported that miR-181a is involved in regulation of prolif-
eration and drug resistance of cancer cells. Thus, we next exam-
ined the expression levels of miR-181a in HepG2 cells and
Hep3B cells by quantitative-RT PCR (qRT-PCR). Notably,
HepG2 cells expressed lower levels of miR-181a compared
to Hep3B cells (Fig. 3a). To test whether miR-181a expression
levels affect sorafenib sensitivity, pre-miR-181a was transfected
into HepG2 cells (Fig. 3b), and the rate of apoptosis was exam-
ined by Hoechst staining. As shown in Figure 3c, sorafenib-
induced apoptosis was reduced by ectopic expression of
miR-181a in HepG2 cells. Conversely, when we inhibited mir-
181a by anti-miR-181a treatment in Hep3B cells (Fig. 3d), sora-
fenib-induced apoptosis was increased (Fig. 3e). These results
suggest that miR-181a plays a critical role in sorafenib resistance.
miR-181a downregulates RASSF1 expression. To elucidate the
target of miR-181a, we performed a database analysis using
miRanda. We searched the candidates in MAPK pathway and
apoptosis-related genes and found RASSF1 as a target gene of
miR-181a (Fig. 4a). Then, we performed a luciferase assay
using reporter plasmid containing WT or mutant sequence of
30 UTR region of RASSF1 (Fig. 4a). Ectopic expression of
WT miR-181a reduced luciferase activity compared to control,
whereas that of mutant miR-181a did not (Fig. 4b). In addi-
tion, pre-miR-181a suppressed RASSF1 expression in HepG2
cells (Fig. 4c), whereas anti-miR181a in Hep3B cells increased
it(Fig. 4d). These results indicate that RASSF1 is a target of
miR-181a.
Knockdown of RASSF1 reduced sorafenib sensitivity. The ﬁnd-
ing that RASSF1 is a target of miR-181a suggests that
RASSF1 may regulate sensitivity to sorafenib. To test this pos-
sibility, we knocked down RASSF1 using two kinds of siRNA
against RASSF1 (Fig. 5a) in HepG2 cells, and cell viability
assay with sorafenib treatment was performed. Knockdown of
RASSF1 signiﬁcantly increased cell viability against sorafenib
(Fig. 5b), suggesting that RASSF1 plays a critical role in sora-
fenib sensitivity.
Fig. 3. miR-181a plays a critical role in sorafenib
resistance. (a) The expression levels of miR-181a of
HepG2 and Hep3B cells were measured by
quantitative-RT-PCR (qRT-PCR). (b) Pre-miR-181a or
negative control miR was transfected into HepG2
cells and miR-181a expression levels were analyzed
by qRT-PCR. (c) Pre-miR-181a or negative control
miR was transfected into HepG2 cells and cells were
treated with sorafenib for 48 h, then apoptosis cells
were measured by Hoechst 33342 staining. (d) Anti-
miR-181a or negative control miR was transfected
into Hep3B cells and miR-181a expression levels
were analyzed by qRT-PCR. (e) Anti-miR-181a or
negative control miR was transfected into Hep3B
cells and cells were treated with sorafenib for 48 h,
then apoptosis cells were measured by Hoechst
33342 staining. *P < 0.05, compared between two
groups.
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Discussion
In the present study, we showed that sorafenib induced more
apoptosis and reduced viability of HepG2 cells compared to
Hep3B cells. Sorafenib treatment in HepG2 cells but not in
Hep3B cells increased expression of apoptosis factor PUMA,
and activated PARP and caspase-3. We found that miR-181a
expression levels were lower in HepG2 cells than in Hep3B
cells, and exogenous miR-181a expression in HepG2 cells
reduced apoptosis, whereas inhibition of miR-181a in Hpe3B
cells increased apoptosis. In addition, we demonstrated that
RASSF1 is a target of miR-181a, and knockdown of RASSF1
increased sorafenib resistance. Together, these results suggest
that miR-181a provokes sorafenib resistance through repression
of RASSF1 expression. Our data provide important insight into
a novel therapeutic strategy against sorafenib resistant HCC
cells by targeting of miR-181a pathway. A critical future chal-
lenge is to explore the relationship between RASSF1 expres-
sion level and treatment response for sorafenib-based
chemotherapy in HCC patients.
It has been reported that miR-181a has oncogenic functions
in various cancers.(16–19) Consistent with these reports, we here
demonstrate that miR-181a induces sorafenib resistance of
HCC cells. We showed that miR-181a directly represses
expression of RASSF1 in HCC cells, which is consistent with
a recent report that miR-181a and miR-181b are highly
expressed in acute promyelocytic leukemia and downregulate
RASSF1 expression.(22) In addition, as well as miR181-a and
miR-181b, miR-181c, which has been shown to promote pan-
creatic cancer cell chemoresistance,(23) are aberrantly
expressed in various cancers, including osteosarcoma and lung
adenocarcinoma.(18,24) These ﬁndings raise the possibility that
miR-181b and miR-181c have a similar function to miR-181a
in HCC cells. In addition, Ji et al.(16) indicate that all members
of miR-181s are associated with HCC cells with features of
hepatic cancer stem cells, suggesting that HepG2 cells, which
have mature features of HCC cells, express lower levels of
miR-181s. Indeed, HepG2 cells expressed lower levels of miR-
181a in our experiment. Therefore, we have additionally
Fig. 4. miR-181a downregulates RASSF1 ex-
pression. (a) Schematic representation of the
predicted and mutated miR-181 binding sites in the
RASSF1 30UTR. (b) HepG2 cells were transfected
with pGL3-30UTR RASSF1 (wild type or mutated) or
pGL3-promoter vector (control) with pRL-TK vector,
and luciferase assay was performed. *P < 0.05,
compared between WT or MUT and pGLpro
control. (c) Relative expression of RASSF1
normalized by ACTIN was analyzed by quantitative-
RT-PCR (qRT-PCR) using HepG2 cells transfected
with pre-miR-181a or negative control miR. (d)
Relative expression of RASSF1 normalized by ACTIN
was analyzed by qRT-PCR using Hep3B cells
transfected with anti-miR-181a or negative control.
*P < 0.05, compared between two groups.
Fig. 5. Knockdown of RASSF1 reduced sorafenib
sensitivity. (a) RASSF1 was knocked down by siRNA
and western blot analysis of RASSF1 was
performed. ACTIN was used as an internal control.
(b) Cells were treated with sorafenib (0–20 lM) and
two kinds of siRNA against RASSF1 (#1 and #2) or
negative control siRNA, and cell viability assay was
performed. *P < 0.05, compared between siRASSF1
and negative control. (c) Summarized models of
miR-181a-mediated sorafenib resistance in
hepatocellular carcinoma cells.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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determined expression levels of miR-181b and miR-181c in
HepG2 and Hep3B HCC cells by qPCR analyses (Fig. S1).
qPCR results showed that miR-181b was signiﬁcantly upregu-
lated in Hep3B cells compared to HepG2 cells similar to miR-
181a, whereas miR-181c levels were comparable. Taken
together, these results suggest that, in addition to miR-181a,
miR-181b may also provoke sorefenib resistance in HCC cells.
RASSF1 is a tumor suppressor gene and elicits apoptosis
through induction of PUMA (Fig. 5c).(25) In contrast, Raf
kinase is known to enhance cell survival through activation of
ERK (Fig. 5c).(26) Raf also binds to MST2, which is a down-
stream regulator of RASSF1, and inhibits RASSF1 signal path-
way (Fig. 5c).(27) Therefore, inhibition of Raf by sorafenib and
low expression of miR-181a may enhance RASSF1-
MST2-PUMA-mediated apoptotic signaling (Fig. 5c). In addi-
tion to Raf, sorafenib simultaneously inhibits growth factor
receptors including VEGFR2 and PDGFR in tumor-associated
endothelial cells, thus inhibiting endothelial cell growth and
neoangiogenesis. Here we show that miR-181a suppresses
apoptotic signaling factor RASSF1, which elicits sorafenib
resistance of HCC cells. Based on our results, miR-181a may
also impact on apoptotic signaling in endothelial cells. If this
is the case, suppression of miR-181a could also enhance
sorafenib-induced apoptosis provoked by inhibition of VEGFR
and PDGFR of endothelial cells.
Recently, several miRNA delivery systems to the liver have
been developed. For example, miR-221 is frequently overex-
pressed in HCC and systemic delivery of a cholesterol-tagged
anti-miR-221 to orthotopic HCC tumors appeared to reduce
tumor cell growth and promote survival.(28) In addition,
adeno-associated virus, lentivirus and nano-sized lipid particles
are also useful methods for delivering miRNA to liver
cancers.(29–32) Therefore, based on our data, development of
the anti-miR-181a delivery system with low side effects may
also be a promising therapeutic approach against HCC.
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